SUMMARY
Chronic heart failure (CHF) is a final link in most diseases of cardiovascular system, and despite the successes in the treatment of CHF, mortality remains high, and the prognosis is disappointing.Currently, the symptoms and objective signs of HF have been described in detail. However, the specific laboratory tests are limited to a single group of markers - natriuretic peptides. The known limitations for natriuretic peptides and the complexity of CHF pathophysiology condition the topicality of searching for other indicators with the aim to search biological and clinical information. In this regard, the biomarkers involved with other pathophysiological mechanisms of CHF appear to be of interest.A significant role of a new biomarker, stimulating a growth factor ST2, also known as “mechanical” myocardial stress is considered in this article. The mentioned biomarker has shown a high prognostic potential in the patients with HF. The increase of its soluble form sST2 is associated with the depth of the damage, the severity of disease course and its outcome. The assessment of prognostic value of the biomarker determination, as the predictor of cardio-vascular diseases and their outcomes has been performed.The topicality of searching for new therapeutic drugs in the combination with “traditional” means of CHF treatment is given in this article.Based on sST2 concentration in the blood, not only CHF degree and effectiveness of performed therapy can be judged, but also more accurately stratify the risk of progressive complications and, thereby, prevent unfavorable clinical outcome.